SHANGHAI, CHINA--(Marketwire - August 21, 2008) - Sinobiomed, Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to announce that it has applied for a Chinese and an international patent for recombinant human kallikrein-1 (rhK1), and for a Chinese patent for an innovative recombinant multivalent tuberculosis vaccine.
